+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Chorionic Gonadotropin Market by Application, End User, Product Type, Technology, Distribution Channel - Global Forecast to 2030- Product Image
Human Chorionic Gonadotropin Market by Application, End User, Product Type, Technology, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Human Chorionic Gonadotropin Market by Application, End User, Product Type, Technology, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674539
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Chorionic Gonadotropin Market grew from USD 1.37 billion in 2024 to USD 1.47 billion in 2025. It is expected to continue growing at a CAGR of 7.50%, reaching USD 2.11 billion by 2030.

Emerging Paradigms in HCG Research and Diagnostics

Human chorionic gonadotropin (HCG) has transcended its origins as a pregnancy marker to become a cornerstone in oncology diagnostics and fertility management. This executive summary introduces the multifaceted significance of HCG, spotlighting its dual application in early gestational monitoring and cancer detection. With ongoing advancements in assay technology and growing demand for point-of-care solutions, stakeholders across diagnostics laboratories, home care platforms and clinical settings are recalibrating strategies to harness HCG’s full potential.

The purpose of this report is to distill complex data into clear strategic guidance. By examining the intersection of technological innovation, regulatory evolution and market dynamics, this summary equips decision-makers with an authoritative overview of current trends. It articulates critical inflection points that will shape R&D investment, commercialization pathways and partnership opportunities over the coming years, setting the stage for informed action in a rapidly evolving diagnostics ecosystem.

Critical Shifts Reshaping the HCG Market Ecosystem

The HCG landscape is experiencing transformative shifts driven by technological breakthroughs and evolving clinical protocols. Automated chemiluminescence immunoassays have improved sensitivity thresholds, enabling earlier detection in oncology and fertility applications. In parallel, the proliferation of digital readout rapid tests has democratized access to home-based pregnancy and ovulation monitoring, reducing time-to-result and enhancing patient engagement.

These innovations coincide with a broader trend toward personalized diagnostics. Fluorescence immunoassay platforms now integrate multiplex capabilities, allowing simultaneous quantification of HCG alongside other biomarkers. Regulatory agencies are also streamlining approval processes for companion diagnostics, accelerating market entry for advanced HCG assays. As telehealth infrastructure expands, remote sample collection and digital reporting are emerging as critical components of an end-to-end HCG testing ecosystem, challenging traditional laboratory-centric models.

Analyzing the 2025 US Tariffs on HCG: Market Consequences

The introduction of new U.S. tariff structures in 2025 has intensified scrutiny of global supply chains for HCG reagents and assay components. Increased duties on imported antibodies and instrumentation have translated into upward pricing pressure, compelling manufacturers to reexamine sourcing strategies. Some firms have responded by localizing production of key reagents in regional facilities to mitigate tariff volatility, while others are negotiating long-term supply contracts to lock in cost efficiencies.

These dynamics have a cascading effect across distribution channels, influencing purchasing decisions in hospitals, pharmacies and online retailers. Diagnostic laboratories face narrowing margins, prompting a reallocation of budgets toward high-throughput platforms that can absorb incremental costs. At the same time, smaller outpatient and home care providers are exploring partnerships with domestic suppliers to secure preferential pricing. Overall, the 2025 tariff regime is catalyzing a recalibration of manufacturing footprints and spurring collaboration between assay developers and local stakeholders.

Segmentation Insights Unveil Diverse Demand Drivers

A nuanced understanding of market segmentation reveals diverse demand drivers for HCG applications. In diagnostics, cancer detection encompasses gestational trophoblastic disease, ovarian cancer and testicular cancer, each necessitating tailored assay sensitivity and specificity. Fertility treatments hinge on IVF monitoring and ovulation surveillance, driving growth in quantitative serum tests. Pregnancy testing remains bifurcated between home-based strips and laboratory-based diagnostics, reflecting both consumer convenience and clinical rigor.

End-user dynamics further delineate market contours. Hospital-based and reference laboratories seek high-throughput serum and urine platforms, while online retail and over-the-counter channels cater to home care settings. General hospitals and maternity wards prioritize integrated diagnostic workflows that align with patient throughput and regulatory compliance. Product type distinctions underscore preferences for rapid saliva tests in decentralized environments, qualitative and quantitative serum assays in clinical labs, and cassette, midstream and strip formats for urine-based screening.

Technological preferences drive another layer of segmentation. Beyond chemiluminescence immunoassays, automated and microplate ELISA formats dominate established channels, while fluorescence immunoassays and digital-readout lateral flow tests gain traction in point-of-care contexts. Distribution pathways span direct sales and hospital supply agreements, complemented by online B2B and B2C ecommerce and both chain and independent pharmacy networks, illustrating the multifaceted routes through which HCG testing solutions reach end users.

Regional Dynamics Highlight Unique Growth Opportunities

Regional dynamics play a pivotal role in shaping the HCG market’s trajectory. In the Americas, robust reimbursement frameworks and established laboratory infrastructure support wide adoption of advanced immunoassay platforms, while emerging point-of-care solutions are gaining momentum in remote and underserved areas. Manufacturers are scaling local production to capitalize on trade agreements and minimize exposure to tariff fluctuations, reinforcing North America’s leadership in HCG diagnostics.

Across Europe, the Middle East and Africa, regulatory harmonization efforts under drive accelerated approval of companion diagnostics, enabling faster entry for novel HCG assays. The region’s heterogeneous healthcare systems foster innovation in kit formatting, with particular emphasis on low-cost lateral flow and rapid test solutions for resource-limited settings. Partnerships between diagnostic companies and local health authorities are driving initiatives to expand fertility monitoring and cancer screening programs.

In the Asia-Pacific region, rising healthcare expenditures and demographic shifts propel demand for both clinical and home-based HCG testing. Rapid urbanization and enhanced digital infrastructure facilitate integration of connected diagnostics platforms. Manufacturers are investing in regional R&D centers to customize assays for genetic and epidemiological profiles, positioning Asia-Pacific as a critical growth frontier for tailored HCG solutions.

Leading Players Driving Innovation and Competition

Key industry players are advancing the HCG market through targeted innovation and strategic alliances. Leading diagnostic instrument manufacturers are deploying next-generation chemiluminescence platforms that deliver higher throughput and reduced per-test costs. Several assay developers have forged partnerships with biotech firms to integrate novel antibody libraries and recombinant antigens, elevating assay performance in oncology and fertility applications.

Collaborations between diagnostic leaders and digital health providers are creating end-to-end solutions that encompass sample collection, data analytics and remote reporting. These alliances are particularly impactful in home care settings, where user-friendly rapid tests with digital readout capabilities are gaining traction. Market entrants specializing in niche assay formats, such as multiplex lateral flow tests, are also intensifying competition by addressing underserved segments within pregnancy monitoring and cancer detection.

Ongoing M&A activity underscores the sector’s consolidation trend, as established players seek to broaden their assay portfolios and secure global distribution networks. Through targeted acquisitions and licensing agreements, companies are strengthening their positions across core segments, from IVF monitoring to gestational trophoblastic disease diagnostics.

Strategic Recommendations to Capitalize on Market Trends

Industry leaders should prioritize investment in point-of-care and digital readout technologies to capture expanding demand for decentralized HCG testing. By co-developing integrated platforms with telehealth providers and patient engagement apps, companies can create seamless end-to-end experiences that reduce diagnostic friction and promote adherence to monitoring regimens.

To mitigate tariff-induced cost pressures, firms ought to diversify their manufacturing footprint across multiple regions and secure long-term supply agreements with local reagent producers. Strategic collaborations with hospital networks and pharmacy chains will ensure preferential listing for both laboratory and retail channels. Moreover, optimizing assay workflows to minimize reagent volumes and instrumentation overhead can preserve margins in high-throughput laboratory environments.

Finally, establishing robust post-market surveillance mechanisms and real-world evidence studies will validate assay performance and reinforce confidence among clinicians and payers. By proactively engaging with regulatory bodies and health authorities, companies can expedite approval pathways for novel HCG assays and strengthen their market positioning.

Comprehensive Methodology Underpinning Analytical Rigor

This research synthesizes data from primary and secondary sources to deliver comprehensive market insights. Primary research encompassed in-depth interviews with key opinion leaders across oncology, reproductive medicine and laboratory management, providing qualitative perspectives on unmet needs and technology adoption.

Secondary research drew from peer-reviewed journals, regulatory filings and proprietary industry databases, ensuring robust triangulation of quantitative data. Patent analysis and clinical trial registries were also reviewed to track innovation trajectories and competitive pipelines. Data collection spanned global markets, with validation checkpoints in the Americas, Europe Middle East & Africa and Asia-Pacific regions.

Analytical rigor was maintained through cross-validation of findings, rigorous data cleansing and the application of established market research frameworks. Expert advisory panels contributed iterative feedback, refining segmentation schemas and ensuring actionable insights. This methodology underpins the report’s credibility, offering stakeholders a transparent path from data acquisition to strategic recommendation.

Synthesis of Critical Insights for HCG Stakeholders

This executive summary has distilled key insights on the evolving HCG landscape, from technological innovations and tariff impacts to segmentation and regional dynamics. Stakeholders in diagnostics laboratories, clinical settings and home care can leverage these findings to inform strategic investments and operational enhancements.

The analysis underscores the imperative to adapt to shifting regulatory frameworks, integrate digital and point-of-care solutions, and align manufacturing strategies with emerging trade policies. By understanding the nuanced preferences across application, end-user, product type, technology and distribution channels, decision-makers can tailor offerings to maximize market penetration and sustain competitive advantage.

As the HCG market continues to expand in oncology, fertility monitoring and pregnancy testing, organizations that embrace collaborative partnerships, agile supply chain models and data-driven product development will be best positioned to capitalize on this dynamic environment. This summary serves as a foundation for deeper exploration and strategic planning.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Cancer Diagnosis
      • Gestational Trophoblastic Disease
      • Ovarian Cancer
      • Testicular Cancer
    • Fertility Treatments
      • Ivf Monitoring
      • Ovulation Monitoring
    • Pregnancy Testing
      • Home Based
      • Lab Based
  • End User
    • Diagnostic Laboratories
      • Hospital Based Laboratories
      • Reference Laboratories
    • Home Care Settings
      • Online Retail
      • Retail Over The Counter
    • Hospitals & Clinics
      • General Hospitals
      • Maternity Wards
  • Product Type
    • Saliva Based
      • Rapid Saliva Tests
    • Serum Based
      • Qualitative Assays
      • Quantitative Assays
    • Urine Based
      • Cassette Tests
      • Midstream Tests
      • Strip Tests
  • Technology
    • Chemiluminescence Immunoassay
    • Enzyme Linked Immunosorbent Assay
      • Automated Elisa
      • Microplate Elisa
    • Fluorescence Immunoassay
    • Rapid Test
      • Digital Readout
      • Lateral Flow
  • Distribution Channel
    • Direct Sales
    • Hospital Supply
    • Online Retail
      • B2B Purchase
      • B2C E Commerce
    • Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck KGaA
  • Ferring International Center S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Organon & Co.
  • Gedeon Richter Plc.
  • Intas Pharmaceuticals Ltd.
  • Bharat Serums and Vaccines Ltd.
  • LG Chem Ltd.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Chorionic Gonadotropin Market, by Application
8.1. Introduction
8.2. Cancer Diagnosis
8.2.1. Gestational Trophoblastic Disease
8.2.2. Ovarian Cancer
8.2.3. Testicular Cancer
8.3. Fertility Treatments
8.3.1. Ivf Monitoring
8.3.2. Ovulation Monitoring
8.4. Pregnancy Testing
8.4.1. Home Based
8.4.2. Lab Based
9. Human Chorionic Gonadotropin Market, by End User
9.1. Introduction
9.2. Diagnostic Laboratories
9.2.1. Hospital Based Laboratories
9.2.2. Reference Laboratories
9.3. Home Care Settings
9.3.1. Online Retail
9.3.2. Retail Over the Counter
9.4. Hospitals & Clinics
9.4.1. General Hospitals
9.4.2. Maternity Wards
10. Human Chorionic Gonadotropin Market, by Product Type
10.1. Introduction
10.2. Saliva Based
10.2.1. Rapid Saliva Tests
10.3. Serum Based
10.3.1. Qualitative Assays
10.3.2. Quantitative Assays
10.4. Urine Based
10.4.1. Cassette Tests
10.4.2. Midstream Tests
10.4.3. Strip Tests
11. Human Chorionic Gonadotropin Market, by Technology
11.1. Introduction
11.2. Chemiluminescence Immunoassay
11.3. Enzyme Linked Immunosorbent Assay
11.3.1. Automated Elisa
11.3.2. Microplate Elisa
11.4. Fluorescence Immunoassay
11.5. Rapid Test
11.5.1. Digital Readout
11.5.2. Lateral Flow
12. Human Chorionic Gonadotropin Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Hospital Supply
12.4. Online Retail
12.4.1. B2B Purchase
12.4.2. B2C E Commerce
12.5. Pharmacies
12.5.1. Chain Pharmacies
12.5.2. Independent Pharmacies
13. Americas Human Chorionic Gonadotropin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Chorionic Gonadotropin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Chorionic Gonadotropin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck KGaA
16.3.2. Ferring International Center S.A.
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.4. Organon & Co.
16.3.5. Gedeon Richter Plc.
16.3.6. Intas Pharmaceuticals Ltd.
16.3.7. Bharat Serums and Vaccines Ltd.
16.3.8. LG Chem Ltd.
16.3.9. Nichi-Iko Pharmaceutical Co., Ltd.
16.3.10. Cadila Healthcare Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET MULTI-CURRENCY
FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET MULTI-LANGUAGE
FIGURE 3. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY GESTATIONAL TROPHOBLASTIC DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TESTICULAR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY IVF MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OVULATION MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY LAB BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RETAIL OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MATERNITY WARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID SALIVA TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY QUALITATIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY QUANTITATIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CASSETTE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MIDSTREAM TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STRIP TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY AUTOMATED ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MICROPLATE ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIGITAL READOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITAL SUPPLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY B2B PURCHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY B2C E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 108. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 109. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 110. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 112. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 113. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 114. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 116. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 117. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 118. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 120. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 121. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 123. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 128. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 130. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 134. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 135. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 136. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 138. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 139. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 141. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 218. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 219. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 221. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 222. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 223. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 225. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 226. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 227. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 228. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 229. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 230. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 232. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 233. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 235. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 236. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 237. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 239. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 240. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 241. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 243. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 244. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 245. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 247. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 248. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 250. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 269. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 271. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 272. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 273. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 275. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 276. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 277. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 279. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 280. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 281. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 283. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 284. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 286. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY CANCER DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 289. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 290. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PREGNANCY TESTING, 2018-2030 (USD MILLION)
TABLE 291. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 293. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 294. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 295. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SALIVA BASED, 2018-2030 (USD MILLION)
TABLE 297. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY SERUM BASED, 2018-2030 (USD MILLION)
TABLE 298. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY URINE BASED, 2018-2030 (USD MILLION)
TABLE 299. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
TABLE 301. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 302. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY ONLINE RETAIL, 2018-2030 (USD MILLION)
TABLE 304. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 3

Companies Mentioned

The companies profiled in this Human Chorionic Gonadotropin market report include:
  • Merck KGaA
  • Ferring International Center S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Organon & Co.
  • Gedeon Richter Plc.
  • Intas Pharmaceuticals Ltd.
  • Bharat Serums and Vaccines Ltd.
  • LG Chem Ltd.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Cadila Healthcare Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.11 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2025-2033 - Product Image

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2025-2033

  • Report
  • 132 Pages
  • Global
From
Human Chorionic Gonadotropin Market Report 2025 - Product Image

Human Chorionic Gonadotropin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chorionic Gonadotropin Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Chorionic Gonadotropin Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Human Chorionic Gonadotropin (HCG) Market 2024-2028 - Product Image

Human Chorionic Gonadotropin (HCG) Market 2024-2028

  • Report
  • 130 Pages
  • Global
From
Pregnant Mare Serum Gonadotropin (CAS 9002-70-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Pregnant Mare Serum Gonadotropin (CAS 9002-70-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 46 Pages
  • Global
From

About the Gonadotropin Market

Gonadotropins are hormones that play a key role in the regulation of reproductive and sexual development. They are used to treat endocrine and metabolic disorders, such as hypogonadism, infertility, and delayed puberty. Gonadotropins are also used to induce ovulation in women with infertility. Gonadotropin drugs are typically administered via injection, and are available in both synthetic and natural forms. Synthetic gonadotropins are typically used to treat infertility, while natural gonadotropins are used to treat hypogonadism. The gonadotropin market is highly competitive, with a number of companies offering products for the treatment of endocrine and metabolic disorders. These companies include Merck, Ferring Pharmaceuticals, Teva Pharmaceuticals, and Ferring Pharmaceuticals. Other companies in the market include Pfizer, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.